Emergent receives $50M BARDA CYFENDUS option and $20M DoD BioThrax option

Emergent BioSolutions Inc.

BARDA awarded $50M option for CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted); deliveries through April 2025.
DoD exercised $20M option for BioThrax (Anthrax Vaccine Adsorbed); $7M delivered Dec 2024, balance in 2025.
Both modifications supplement existing IDIQ contracts with BARDA (HHSO100201600030C) and DoD (W911SR24D0001).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.